Patrick Hwu: Ben Creelan about the exciting potential of TIL Therapy for lung cancer

Patrick Hwu shared a post on LinkedIn:

”Great conversation with Dr. Ben Creelan about the exciting potential of TIL Therapy for lung cancer.

Check out our discussion to learn more about this promising approach and how we’re pushing the boundaries to bring new hope to our patients.”

Source: Patrick Hwu/LinkedIn

Patrick Hwu, MD, currently serves as the President and CEO of Moffitt Cancer Center. With a focus on understanding the dynamics between tumors and the immune system, Dr. Hwu’s research has been pivotal in advancing gene-modified T cell therapy. He notably contributed seminal work on the development of the first chimeric antigen receptor aimed at combating cancer. His research portfolio extends to vaccines, adoptive T-cell therapies, and mechanisms of immune resistance.

Ben Creelan is a Thoracic Oncologist at Moffitt Cancer Center and an Associate Professor at USF Health Medicine. As a translational scientist, his research focuses on developing novel cell therapies, such as CAR-T and TIL, for treating solid tumors, particularly lung cancers. His work aims to identify new antigenic targets for immune cells and translate these discoveries into innovative early-phase clinical trials.